Get the Stockscreener App
1.91
6.83%
-0.14
After Hours:
1.91
Metagenomi Inc stock is traded at $1.91, with a volume of 234.67K.
It is down -6.83% in the last 24 hours and down -22.04% over the past month.
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering approaches to date. The genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs).
See More
Previous Close:
$2.05
Open:
$2.04
24h Volume:
234.67K
Relative Volume:
0.11
Market Cap:
$71.48M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-1.55%
1M Performance:
-22.04%
6M Performance:
-29.26%
1Y Performance:
-82.76%
1-Day Range:
$1.90
$2.077
1-Week Range:
$1.87
$2.095
52-Week Range:
$1.61
$11.86
Metagenomi Inc Stock (MGX) Company Profile
Name
Metagenomi Inc
Sector
Industry
Phone
(510) 871-4880
Address
5959 HORTON STREET, EMERYVILLE
Compare MGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGX
Metagenomi Inc
|
1.91 | 71.48M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Metagenomi Inc Stock (MGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Initiated | H.C. Wainwright | Buy |
| May-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-05-24 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-24 | Initiated | Chardan Capital Markets | Buy |
| Mar-05-24 | Initiated | JP Morgan | Overweight |
| Mar-05-24 | Initiated | Jefferies | Buy |
| Mar-05-24 | Initiated | TD Cowen | Outperform |
| Mar-05-24 | Initiated | Wells Fargo | Overweight |
View All
Metagenomi Inc Stock (MGX) Latest News
Metagenomi achieves gene integration breakthrough - Investing.com
Metagenomi Announces Publication in Nature Communications - GlobeNewswire
Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances ... - Bluefield Daily Telegraph
Metagenomi Breakthrough: New CRISPR System Enables Large Gene Integration | MGX Stock News - StockTitan
Rhumbline Advisers Increases Position in Metagenomi, Inc. (NASDAQ:MGX) - Defense World
Metagenomi, Inc. (MGX) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
Metagenomi CFO Pamela Wapnick sells stock for $3,389 - Investing.com India
Metagenomi CFO Pamela Wapnick sells stock for $3,389 By Investing.com - Investing.com UK
Metagenomi, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights – MGX - ACCESS Newswire
MGX LAWSUIT ALERT: Levi & Korsinsky Notifies Metagenomi, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Metagenomi, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before November 25, 2024 to Discuss Your RightsMGX - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 25, 2024 in Metagenomi LawsuitMGX - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 25, 2024 in Metagenomi, Inc. LawsuitMGX - ACCESS Newswire
Shareholders that lost money on Metagenomi, Inc.(MGX) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More - ACCESS Newswire
Metagenomi, Inc. (MGX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Metagenomi advances gene editing therapies into 2025 - MSN
Shareholder Rights Advocates at Levi & Korsinsky Investigate Metagenomi, Inc. (MGX) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Metagenomi, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before November 25, 2024 to Discuss Your RightsMGX - ACCESS Newswire
Levi & Korsinsky Reminds Metagenomi Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 25, 2024MGX - ACCESS Newswire
MGX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Metagenomi, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Metagenomi, Inc. (NASDAQ:MGX) Receives $16.67 Average Price Target from Analysts - MarketBeat
Metagenomi, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for Details- MGX - ACCESS Newswire
A look into Metagenomi Inc (MGX)’s deeper side - SETE News
Metagenomi, Inc. (NASDAQ:MGX) Short Interest Update - MarketBeat
Levi & Korsinsky Reminds Metagenomi, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 25, 2024MGX - ACCESS Newswire
Peapod Lane Capital LLC Invests $1.27 Million in Metagenomi, Inc. (NASDAQ:MGX) - MarketBeat
Metagenomi, Inc. (NASDAQ:MGX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
FINAL MGX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Metagenomi, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
These two noteworthy penny stocks can do wonders! Here's more insights into Alto Ingredients, Metagenomi a - The Economic Times
Alto Ingredients And 2 Other US Penny Stocks To Watch - Simply Wall St
SG Americas Securities LLC Invests $43,000 in Metagenomi, Inc. (NASDAQ:MGX) - Defense World
Lead Plaintiff Appointed to Represent Investors in Metagenomi Class Action - TradingView
MGX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Metagenomi, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference - GlobeNewswire
Metagenomi Inc [MGX] Insider Activity: An Update for Investors - Knox Daily
Quarterly Metrics: Quick and Current Ratios for Metagenomi Inc (MGX) - The Dwinnex
MGX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Metagenomi, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Analysts review Metagenomi Inc’s rating - Knox Daily
Is Metagenomi Inc (MGX) worth investing in despite its overvalued state? - US Post News
MGX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Metagenomi, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Market Watch Highlights: Metagenomi Inc (MGX) Ends on an Downturn Note at 2.69 - The Dwinnex
Neutral On Metagenomi's Promising Yet Highly Speculative Gene Editing Potential - Seeking Alpha
Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer - GlobeNewswire Inc.
The Market Doesn't Like What It Sees From Metagenomi, Inc.'s (NASDAQ:MGX) Revenues Yet As Shares Tumble 26% - Simply Wall St
Brokerages Set Metagenomi, Inc. (NASDAQ:MGX) Price Target at $16.67 - MarketBeat
Investors Who Lost Money With NASDAQ:MGX Shares Should Contact the Shareholders Foundation in Connection With Lawsuit Against Metagenomi, Inc - ACCESS Newswire
Stargate Project’s healthcare winners: AI-led biotechs and Metagenomi - MSN
FINAL REMINDER MGX DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Metagenomi, Inc. Investors to Participate in the Class Action Lawsuit! - ACCESS Newswire
StockWatch: Up-to-$500B AI Venture Sparks Investor Interest, and Questions - Genetic Engineering & Biotechnology News
Metagenomi, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before November 25, 2024 to Discuss Your Rights – MGX - ACCESS Newswire
Metagenomi, Inc. (NASDAQ:MGX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Metagenomi Inc Stock (MGX) Financials Data
There is no financial data for Metagenomi Inc (MGX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):